# NIAID - VRC - Pre-Clinical Assessment of monoclonal antibodies and other promising vaccines/agents

> **NIH NIH N01** · LEIDOS BIOMEDICAL RESEARCH, INC. · 2022 · $2,198,288

## Abstract

The VRC is dedicated to improving global human health through the rigorous pursuit of effective vaccines for human diseases. The NIAID mission and scope includes rapidly responding to infectious disease outbreaks through research, development and clinical testing of therapeutics and vaccines against diseases caused by pathogens that threaten public health such as, HIV, pandemic influenza, and emerging and re-emerging infectious diseases like Ebola, Zika, and Malaria.

## Key facts

- **NIH application ID:** 10722428
- **Project number:** 75N91019D00024-P00006-759101900135-1
- **Recipient organization:** LEIDOS BIOMEDICAL RESEARCH, INC.
- **Principal Investigator:** CHRISTOPHER CASE
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $2,198,288
- **Award type:** —
- **Project period:** 2019-09-30 → 2027-09-11

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10722428

## Citation

> US National Institutes of Health, RePORTER application 10722428, NIAID - VRC - Pre-Clinical Assessment of monoclonal antibodies and other promising vaccines/agents (75N91019D00024-P00006-759101900135-1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10722428. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*